Sysmex and Eisai shared research from their joint effort to create a diagnostic blood test for Alzheimer's disease at this week's International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) in Barcelona, Spain.
As part of a nonexclusive agreement to create diagnostic agents for dementia, researchers from the companies compared the performance of the plasma beta-amyloid ratio measured using the Sysmex HISCL automated immunoassay system with that of amyloid status on positron emission tomography (PET) imaging as determined by the Centiloid method. Their technique was assessed in a discovery study in 180 patients and in a validation study involving 191 patients who were clinically diagnosed with mild Alzheimer's disease or mild cognitive impairment.
In the discovery study, the researchers found that the plasma beta-amyloid ratio was significantly lower in the group of patients with positive beta-amyloid results on PET than those with negative PET results. Furthermore, the ratio yielded an area under the curve of 0.93, sensitivity of 97.5%, and specificity of 80.8% for predicting beta-amyloid PET status, according to the authors.
Other results also suggested that the plasma beta-amyloid ratio could potentially indicate the presence of amyloid pathology in the brain earlier than it could be detected on PET, according to the authors.